Moderate ResearchWeight LossMetabolic

BAM-15

BAM15

Mitochondrial Uncoupler | Metabolic Enhancer

Half-life

~1.7 hours

Chain length

Not applicable

Reference frequency

Once or twice daily with meals

Research overview

DoseGear research brief

BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders. Unlike traditional uncouplers like DNP which have serious toxicity concerns, BAM-15 demonstrates a superior safety profile while effectively increasing energy expenditure and fat oxidation. Research in mice shows BAM-15 reduces body fat without affecting food intake, lean mass, or body temperature. It is approximately 7-fold more potent than DNP and does not induce the dangerous hyperthermia associated with older uncouplers. Note: BAM-15 is a small molecule compound, not a peptide, but is commonly sold alongside peptide products.

Mechanism of action

BAM-15 targets the inner mitochondrial membrane, enhancing proton permeability and dissipating the proton gradient. This uncouples electron transport from ATP synthesis, forcing mitochondria to increase respiration and burn more substrates (particularly fat) to maintain energy production. BAM-15 activates AMP-activated protein kinase (AMPK) in response to ATP depletion, promoting glucose uptake and fatty acid oxidation. It also activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), enhancing mitochondrial biogenesis. Unlike DNP or FCCP, BAM-15 does not depolarize plasma membranes or induce apoptosis at effective concentrations, explaining its improved safety profile.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Synthetic small-molecule mitochondrial uncoupler; it is not a peptide.

What it is researched for

Preclinical obesity and metabolic-disease research through mitochondrial proton-gradient dissipation and substrate oxidation.

Research observation window

Not reported in the reviewed compound-specific evidence.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

No sourced lyophilized-vial injectable protocol is listed for this profile.

Safety context

Reported side effects

Generally well-tolerated in research
Possible mild increase in body temperature (less than DNP)

Contraindications & cautions

Hyperthyroidism or thyroid disorders
Heart conditions
Pregnancy or breastfeeding
Use of other mitochondrial uncouplers (DNP, FCCP)
Fever or active infection

Scientific references

01
Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice
Scientific citationMitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nature Communications (2020).
02
BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control
Scientific citationBAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control. EMBO Molecular Medicine (2020).
03
BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases
Scientific citationBAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases. PMC Review (2023).
04
Beneficial effects of simultaneously targeting calorie intake and calorie efficiency in diet-induced obese mice
Scientific citationBeneficial effects of simultaneously targeting calorie intake and calorie efficiency in diet-induced obese mice. Clinical Science (2024).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity